[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Friday, 1 December 2006, 12:50 GMT
New Aids drugs 'soaring in cost'
By Grant Ferrett
BBC World Service

Campaigners protesting about the cost of second-line drugs
World Aids Day has seen protests over second-line drugs costs
The cost of drugs to tackle the effects of Aids is again soaring, five years after trade negotiators made what was thought to be a breakthrough at talks in Doha to allow greater access to drugs for those living in developing countries.

Since the Doha deal, the price of HIV treatments in developing countries - where the majority of HIV-positive people live - has come down dramatically, in some areas from $10,000 a year per person to $150.

"Those medicines were very expensive because they were all under patent," explained Sarah Bowsley, health correspondent of the UK's Guardian newspaper.

"The Doha declaration was thought to be a way of actually allowing generics - cheap, copycat versions - into the field."

This is not only because of the availability of generic products, but because many of the pharmaceutical companies lowered the price of their own branded drugs as well. There are now five times as many people receiving drug treatment for HIV compared with five years ago.

Second-line drugs

But the world is still far short of providing drugs for all of the estimated six million who need them.

And Tido von Schoen-Angerer of Medecins Sans Frontieres said the old problem of expensive drugs is now reappearing.

Aids treatment drugs
Pharmacies could be fully stocked, but without enough doctors and nurses, there's just no way that people waiting outside the clinic can get the medicine
Dirk van Eeden, Abbott pharmaceuticals
"What we are seeing, five years after Doha, is that prices are again on the increase," he said.

"If patients need newer drugs, that means costs go up 10 times - or, in some countries, up to 50 times. This is a very worrying trend."

Prices are going up because these new treatments - known as second-line drugs - are more expensive than their predecessors.

The new medicines are needed because HIV is changing - and for some patients, existing drugs lose their effectiveness.

The new versions are often either more expensive or simply not available to patients in poorer countries.

Until now, India has been the main producer of generic drugs - but in 2005, the country was obliged to change its legislation to comply with World Trade Organisation rules, meaning that drugs invented after that point cannot be made in India by the generic companies.

The Guardian's Sarah Bowsley said that there is "a lot of pressure" on the Indian government by the pharmaceutical companies, to stop them producing generic versions of the newer drugs.

"They know that after the second-line Aids drugs we're also talking about cancer drugs, diabetes, heart disease," she said.

"It is all the things that affect us in the West - and actually affect populations in developing countries too."

Initiatives

Drug manufacturers argue that patents are needed to protect their investments. They spend years developing drugs - and if these are simply copied, they lose out.

Worker in an Indian drug development plant
India is under pressure to stop generics of new drugs being created
Dirk van Eeden, spokesman for one of the world's biggest drugs companies, US-based Abbott, said that price is "not the real stumbling block" - insisting the problem is the lack of healthcare workers and infrastructure.

"Sub-Saharan Africa has a quarter of the global HIV burden - yet only 3% of all of the healthcare workers in the world," he said.

"Pharmacies could be fully stocked, but without enough doctors and nurses, there's just no way that people waiting outside the clinic can get the medicine."

Certainly, where campaigners and pharmaceutical companies agree is that what is needed is the political will at the highest levels to take co-ordinated, global action.

If the world is to help the millions living with HIV in poorer countries, a massive injection of cash and commitment is needed.

"There is only so much you can expect from companies... there is a great need for public leadership on this issue," said Mr von Schoen-Angerer.

"There is an absence of government support for these kind of initiatives, and without public leadership this will not be resolved."


RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites



FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

PRODUCTS & SERVICES

Americas Africa Europe Middle East South Asia Asia Pacific